Latex Allergy Market to Experience Substantial Growth Reports MRFR

Pune, India, March, 2023 /press release/- Market Research Future Published a Half-Cooked Research Report on Global Latex Allergy Market Research Report.

Overview:

The global latex allergy market is expected to grow with a 7.4% CAGR to reach USD 2,837.7 during the forecast period (2022-2030), claims Market Research Future (MRFR) in a well-studied report. Exposure to substances made of latex (natural rubber) can trigger an allergy in a person by directly affecting that person’s immune system. This leads to the release of antibodies and antihistamines which causes itchy hands, skin rash, hives, and eczema. People who use it continually may find this type of allergy troubling them more. For instance, workers in the healthcare industry can get affected by this disease more than the regular populace. A study by Centers for Disease Control and Prevention reveals, 8 to 12% of healthcare workers are susceptible to this allergy, compared with 1 to 6% of the general population. This type of allergy can further enhance the chances of people getting affected by diseases such as Asthma, Rhinitis, Anaphylaxis, and others. 

However, the disease can turn fatal if the allergy causes anaphylaxis. Signs will be numerous. Only an appropriate measure can keep it in check.

Industry Trends:

The Association of Surgical Technologists has recently published the updated version of the guideline “Guideline for Best Practices for the Natural Rubber Latex Allergy Patient” to instruct healthcare personnel about the importance of safety while treating a patient in the operation theatre or anywhere.

Aterica Health Inc., a digital health company, based out of Canada, in 2017 developed Veta Smart Case & App, for EPIPEN auto-injectors which can assist patients with early detection of signs related to anaphylaxis, a disease mostly caused by allergies caused by latex.

Segmentation:

The global latex allergy market can be segmented by exposure type, diagnosis type, reaction type, and treatment.

Based on of exposure the market is segmented as latex gloves, food containing latex substances. 

Diagnosis-type consists diagnosis type the market is segmented as skin test and allergy test.

On the basis of reaction type, the market is segmented into the systemic reaction, allergic contact dermatitis, irritant contact dermatitis, asthma, anaphylaxis, and rhinitis. 

Type-based segmentation requires epinephrine injection, allergy medications: inhaler/albuterol, antihistamine, asthma medication, corticosteroids, etc.

Explore In-depth Details: Latex Allergy Market Research Report

Regional Analysis

Geographically, the global latex allergy market envelops North America, Asia Pacific (APAC), Europe, and the Middle East & Africa (MEA).

North America has taken a considerable lead in the global market by generating the maximum revenue share. Major pharmaceutical companies are based out of the U.S. owing to which the regional market is prospering. In addition, awareness related to such diseases and technological advancements in the healthcare sector coupled with the availability of possible alternatives to reduce the use of latex spur the market growth.

The APAC is expected to be one of the most significant regions. The huge population base is a major reason driving the market ahead. At the same time, the healthcare segment is also getting definite boosting.

Market Competition:

The market is densely packed with several international pharmaceutical companies constantly striving to stay afloat in this competition. New product launch, investment in research & developments, and merger & acquisitions are methods that the companies are applying to expand their market portfolio.

Some of the key players in this market are: 3M (USA), Alcon Inc. (US), Allerayde UK Ltd (UK), Allergy Hero (UK), Array BioPharma Inc. (US), AstraZeneca (UK), Aterica (Canada), Boehringer-Ingelheim (Germany), Dey Labs (US), GlaxoSmithKline (UK), Johnson & Johnson (US), Merck (US), Nektar Therapeutics (US), Novartis AG (Switzerland), Rocky Mountain Diagnostics (US), Sanofi (France), and others.